Other News Items

Three Research Fellows promoted to Instructor


We are please to announce that three Research Fellows in the Gordon Center have been promoted to the title of Instructor. Congratulations to Kai Bao, Fangxu Xing, and Gengyang Yuan!

Research Agreement Signed with Cerveau Technologies


Cerveau Technologies Inc. signed an agreement with the MGH Gordon Center to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

As part of the agreement, Cerveau will contract with the Gordon Center for Medical Imaging, a research center and PET imaging facility within MGH, to manufacture and supply the [18F]MK-6240 needed for initiatives in the greater Boston area. “We are glad to be part of the effort to make Tau PET available to the New England research community as it is becoming a tool of choice for in vivo assessment of tau pathology in many brain disorders,” said Dr. Georges El Fakhri, Director of the MGH Gordon Center.

According to Dr. Keith Johnson, leader of the Aging NeuroImaging Program at the MGH Gordon Center, and the Harvard Aging Brain Study, “the ability to detect tau brain pathology in living humans is a major medical breakthrough. The value of this novel technology has already been demonstrated to improve the likelihood we can develop treatments for Alzheimer’s disease. In addition, however, brain tau deposition is a major player in chronic traumatic encephalopathy, fronto-temporal dementia, and several forms of Parkinsonism. This means that successful research program initiatives for novel radio-pharmaceuticals such as MK6240 are an important advance toward refinement and optimization of tau PET, which is the rapidly developing biomarker technology aimed at tracking tau pathology in a variety of brain disorders.”

“Cerveau welcomes this opportunity to work with the MGH researchers, who have a very successful history of leadership in this field to understand the application of MK-6240 and how it may benefit patients with brain diseases. The collaboration with the Gordon Center at MGH will also provide access to our pharmaceutical partners in support of various therapy trials and support our global production network in Europe, Canada, Japan, China, Singapore, Australia and the United States as well facilitate novel research at MGH in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.

Read more: https://www.businesswire.com/news/home/20180208005974/en

Brain PET scan

2018 Gordon Center Winter Holiday Party


A warm thank you to everyone who joined us for our winter holiday party.

2018 Human Amyloid Imaging Conference


The 12th Human Amyloid Imaging Conference took place in Miami, Florida on January 17-19, 2018.

Dr. Keith Johnson organized the event with the help of Drs. Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley).

This year’s conference featured two cross-disciplinary keynote speakers: Drs. William Seeley (University of California, San Francisco) and Peter Davies (Northwell Health). They discussed what the presence of brain amyloid means, how it should be measured, how it changes, and what it signifies.

The 2018 meeting included podium and poster presentations on cutting edge research into biomarkers for Alzheimer’s-related disease. It drew more than 400 attendees and showcased 130 posters from research groups spanning North America, Europe, East Asia, and Australia.

For more information, please see the Human Amyloid Imaging Conference website.

Poster Presentations at the 2018 Human Amyloid Imaging Conference

Annual Holiday Party


Thank you to everyone who made it out to our annual holiday party. Take a look at the gallery below for some of the highlights of the evening.

Happy Holidays


For the upcoming holidays, we will be closed Monday, December 26, and Monday, January 2. We wish you a healthy and happy holiday season!

Happy Holidays & Best Wishes for the New Year

PET Production Facility


The production facility is a cGMP/FDA registered PET drug manufacturer that consists of an ISO Class 8 manufacturing area, an ISO Class 7 cleanroom and a quality control lab. The core laboratories are equipped with over 20 mini cells and automated chemistry modules used primarily for the synthesis of 18F, 11C and 13N radiopharmaceuticals.

Click on video for more Dr. Daniel Yokell giving an overview of the facility

Dr. Quanzheng Li Promoted to Associate Professor


We are pleased to announce Dr. Quanzheng Li's promotion to Associate Professor at Harvard Medical School. Dr. Li received his doctoral degree in Electrical Engineering in 2005 from the University of Southern California before joining Masschusetts General Hospital in 2011. He has published several works on image reconstruction and kinetic modeling, and is the recipient of several honors including the IEEE-NPSS Early Achievement Award.

Dr. Quanzheng Li

Dr. Quanzheng Li